LPL Financial LLC Boosts Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

LPL Financial LLC lifted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 12.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 52,392 shares of the biopharmaceutical company’s stock after acquiring an additional 5,708 shares during the quarter. LPL Financial LLC’s holdings in ACADIA Pharmaceuticals were worth $1,255,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. purchased a new position in shares of ACADIA Pharmaceuticals in the first quarter worth about $572,000. HighTower Advisors LLC acquired a new position in shares of ACADIA Pharmaceuticals during the 1st quarter worth $1,077,000. MetLife Investment Management LLC grew its stake in ACADIA Pharmaceuticals by 54.0% in the 1st quarter. MetLife Investment Management LLC now owns 66,351 shares of the biopharmaceutical company’s stock valued at $1,607,000 after acquiring an additional 23,265 shares during the last quarter. Rhumbline Advisers lifted its holdings in ACADIA Pharmaceuticals by 3.9% in the 1st quarter. Rhumbline Advisers now owns 133,444 shares of the biopharmaceutical company’s stock valued at $3,232,000 after purchasing an additional 5,011 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in ACADIA Pharmaceuticals during the 1st quarter valued at $1,380,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ:ACAD opened at $22.57 on Thursday. The business has a 50 day simple moving average of $23.28 and a two-hundred day simple moving average of $24.97. The firm has a market capitalization of $3.71 billion, a PE ratio of -24.53 and a beta of 0.62. ACADIA Pharmaceuticals Inc. has a 1 year low of $14.45 and a 1 year high of $33.99.

Analyst Upgrades and Downgrades

Several research firms have commented on ACAD. HC Wainwright reissued a “buy” rating and set a $33.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, August 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $42.00 target price on shares of ACADIA Pharmaceuticals in a research note on Tuesday, August 22nd. JPMorgan Chase & Co. upgraded shares of ACADIA Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their target price for the company from $29.00 to $32.00 in a research report on Tuesday, October 10th. StockNews.com downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. Finally, UBS Group initiated coverage on ACADIA Pharmaceuticals in a report on Tuesday, October 17th. They set a “buy” rating and a $33.00 price target for the company. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.67.

Insider Activity at ACADIA Pharmaceuticals

In related news, CFO Mark C. Schneyer sold 10,000 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $29.00, for a total value of $290,000.00. Following the transaction, the chief financial officer now directly owns 15,682 shares of the company’s stock, valued at approximately $454,778. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CFO Mark C. Schneyer sold 10,000 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $29.00, for a total value of $290,000.00. Following the completion of the sale, the chief financial officer now owns 15,682 shares in the company, valued at approximately $454,778. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Austin D. Kim sold 16,369 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Friday, October 6th. The shares were sold at an average price of $21.96, for a total transaction of $359,463.24. Following the completion of the sale, the executive vice president now owns 45,857 shares of the company’s stock, valued at approximately $1,007,019.72. The disclosure for this sale can be found here. Insiders have sold a total of 79,932 shares of company stock valued at $1,833,547 in the last ninety days. Company insiders own 27.50% of the company’s stock.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.